Sarepta shares tumble on trial failure, weak Elevidys outlook
Update: 2025-11-04
Description
Sarepta's Duchenne drugs face setback, shares plummet: Despite the company's insistence that the pandemic disrupted trial participation, a major clinical trial testing two of its drugs failed to produce strong results, deepening pressure from investors and regulators. Sarepta plans to meet with the US drug regulator to discuss turning current approvals into permanent ones, while families continue to access treatments.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
